AlzeCure Pharma AB appointed Martin Jönsson as the company’s new CEO.

A specially designed clinical study that was the first disease prevention trial to study Alzheimer’s disease drugs with different mechanisms of action from two different pharmaceutical companies failed to hit the primary endpoint.

Little headway has been made in developing a treatment for Alzheimer’s disease, but that could be changing.

The best-known genetic marker for Alzheimer’s disease is ApoE4 – a form of apolipoprotein E – which is a protein involved in repairing neurons injured by aging, stroke or other reasons.

Investigators at the Case Western Reserve University School of Medicine identified a previously unknown gene and the resultant protein that may potentially slow the progress of Alzheimer’s disease.

Nurix Therapeutics Inc. is developing drugs that can specifically target one protein within the hundreds or thousands of extremely similar proteins in the body, ultimately enabling them to regulate hard-to-drug or ‘undruggable’ proteins.

Carlsbad, California-based Ionis Pharmaceuticals licensed the company’s IONIS-MAPTRX antisense therapy to leading biotech firm Biogen Inc.

Shares of Aquestive Therapeutics were up more than 18 percent following approval from the U.S. Food and Drug Administration for Exservan, a treatment for amyotrophic lateral sclerosis (ALS).

For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.

A study of more than a thousand former professional soccer players has uncovered significantly more deaths from brain disease than among non-players.